Astra's Soriot Says Slow Pace of Brexit Talks an Area of Concern
- “There’s no clarity in terms of trade,” Soriot says
- EU official said she doubts trade talks will start next month
Why U.K. Consumers May Miss Spanish Oranges, Irish Beef
This article is for subscribers only.
AstraZeneca Plc Chief Executive Officer Pascal Soriot said the lack of progress in negotiations between the U.K. and the European Union on their future ties is worrying, and could hinder the drugmaker’s exports to foreign markets after Brexit.
“So far, we don’t have any idea how products will be shipped across borders,” Soriot said in an interview Monday. His company, the U.K.’s second-biggest drugmaker, sells medicines ranging from Crestor cholestrol pills and acid reflux drug Nexium to cancer treatment Zoladex across the world. “There’s no clarity in terms of trade.”